Discovery and development of ML3000

Inflammopharmacology

Volumn 9, Issue 1-2, 2001, Pages 101-112

  Laufer, S ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

5 lipoxygenase; 2,2 Dimethyl 6 (4 chlorophenyl) 7 phenyl 2,3 dihydro 1H pyrrolizine 5 yl acetic acid; Anti inflammatory; Cyclooxygenase; Gastrointestinal; Leukotriene; ML3000; NSAID

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIPYRETIC ANALGESIC AGENT; ANTITHROMBOCYTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BRONCHODILATING AGENT; DICLOFENAC; INDOMETACIN; LEUKOTRIENE; LICOFELONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRROLIZINE DERIVATIVE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; LIVER TOXICITY; MOUSE; NONHUMAN; OSTEOARTHRITIS; OXIDATION REDUCTION REACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0034946179     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856001300248371     Document Type: Conference Paper

References (22)

1. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl) -7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals
2. Initial clinical studies with ML3000 in osteoarthritis
3. Pharmacokinetics, pharmacodynamics, and minimum effective clinical dose of intravenous nicardipine
4. Anti-inflammatory 2,3-dihydro-1H-pyrrolizine. 13. Isomeric (diaryl-dihydropyrrolizinyl) acetic acids and 2-(diaryldihydropyrrolizinyl)-ethanols
5. NSAID induced ulcers. An emerging epidemic?
6. Antioxidant-based inhibitors of leukotriene biosynthesis. The discovery of 6-[1-[2-(hydroxymethyl)phenyl]-1-propen-3-yl]-2,3-dihydro-5-benzofuranol, a potent topical antiinflammatory agent
7. Pharmacological properties of a new anti-inflammatory compound, alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolactone (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase
8. Methods of assessment of GI tract injury and early endoscopic results with ML3000
9. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal anti-inflammatory drugs
10. 6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase
11. Synthesis and quantitative structure-activity relationships of diclofenac analogues
12. Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage
13. Hydroxamic acid inhibitors of 5-lipoxygenase
14. Hydroxamic acid inhibitors of 5-lipoxygenase: Quantitative structure-activity relationships
15. The pharmacological profile of ML3000: A new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase
16. ML3000 reduces gastric prostaglandin synthesis without causing mucosal injury
17. Pathogenesis of NSAID gastropathy: Are neutrophils the culprits?
18. Antiarthritic profile of BF-389 - A novel anti-inflammatory agent with low ulcerogenic liability